Marker Therapeutics Inc
GX1
Company Profile
Business description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Contact
2450 Holcombe Boulevard
Suite e BCM-A, MS: BCM251
HoustonTX77021
USAT: +1 713 400-6400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Are small caps finally back?
Does renewed investor interest point to a structural shift in the underperforming factor?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
The latest update from our Industry Pulse report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,329.10 | 50.90 | 0.55% |
| CAC 40 | 8,241.32 | 34.45 | 0.42% |
| DAX 40 | 24,131.56 | 19.57 | -0.08% |
| Dow JONES (US) | 46,590.41 | 334.33 | -0.71% |
| FTSE 100 | 9,574.85 | 59.85 | 0.63% |
| HKSE | 25,967.98 | 186.21 | 0.72% |
| NASDAQ | 22,740.40 | 213.27 | -0.93% |
| Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
| NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
| S&P 500 | 6,699.40 | 35.95 | -0.53% |
| S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
| SSE Composite Index | 3,922.41 | 8.65 | 0.22% |